Skip to main content

Table 1 SITC 2018 Biomarkers Workshop Data Sharing Partnerships

From: SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art

Name of Institution Objective (related to IO/Biomarkers) Perspective
National Cancer Institute (NCI) Address knowledge gaps in cancer immunotherapy to optimize clinical trial design. Developed the CIMAC-CIDC Network from the Cancer Moonshot Initiative to establish a standing network of laboratories and data commons for a systematic approach to biomarker discovery and validation. Government
Cancer Immune Monitoring and Analysis Centers (CIMAC) and Cancer Immunologic Data Commons (CIDC) Network Provide systematic support for correlative studies in immunotherapy trials through a standing network of laboratory centers (CIMACs) for immune profiling and analysis, and a data center (CIDC) for data repository, integration and analytical pipelines. The goal is to build the framework for a sustainable immuno-oncology data resource serving the NCI trial networks and funded programs and eventually the larger research community. Government-Academic-Private Partnership
Foundation for the National Institutes of Health (FNIH) Accelerate biomedical research through collaborations between NIH and leading public and private institutions. (E.g. FNIH manages the Biomarkers Consortium, a public-private biomedical research partnership for identification and development of high-impact biomarkers.) Government
The Partnership for Accelerating Cancer Therapies (PACT) Enhance ongoing efforts within the CIMAC-CIDC network to provide a systematic approach to IO biomarker investigation in clinical trials. Public-Private Partnership
Parker Institute for Cancer Immunotherapy (PICI) Utilize a collaboration-based model with specific considerations for standardized data and specimen sharing across all platforms. Public-Private Partnership
Cancer Immunotherapy Trials Network (CITN) Pair cutting edge clinical trials with correlative biomarker studies. Implementation of centralized operations, quality specimen collection and processing, competent biobanking, protocols and amendment management, real-time immune monitoring assays, collaborations with expert laboratories, and standardized data integration. Academia
Biden Cancer Initiative Develop and drive progress in cancer research, especially in assay/data standardization and harmonization - under Vice President Biden and Dr. Jill Biden’s Moonshot Initiative. Non-profit
National Institute of Standards and Technology (NIST) Apply transparent, open-sourced standards to cancer research and clinical care. Public-Private Partnership
Alliance-NCI irAE Biorepository Provide an efficient centralized repository for acquisition, organization and distribution of biospecimens in clinical trials; to improve treatment of severe irAEs. Public-Private Partnership
Bill & Melinda Gates Medical Research Institute (The Gates Foundation) Utilize IO biomarker strategies to develop drugs and vaccines for tuberculosis, malaria and enteric disease. Non-profit